Psychemedics Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Powell Anderson Capital Partners LLC, was filed 17 Dec 2024.
Psychemedics Corp: what insiders have been doing
Every trade that managers of Psychemedics Corp disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. Psychemedics Corp has had no insider filing for more than a year; the last one goes back to 17 December 2024.
Looking back to 2006, when coverage begins, insiders filed 47 purchases and 52 sales.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Who traded when
BuySaleSince the insiders bought
- +3.4%Entry US$1.74 · Close at T+365 US$1.80
- -40.2%Entry US$3.21 · Close at T+365 US$1.92
- -41.4%Entry US$4.92 · Close at T+365 US$2.88
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2024FY ended December 2024 · cache
- 9,850 shares@ US$1.874.0% of flowCommon StockSEC:0001104659-24-129515:3Canonical exit: 17 Mar 2025 (T+90)
- 30,000 shares@ US$1.9712.8% of flowCommon StockSEC:0001104659-24-129515:1Canonical exit: 16 Mar 2025 (T+90)
- 80,000 shares@ US$1.8888.7% of flowCommon StockSEC:0001104659-24-129515:0Canonical exit: 13 Mar 2025 (T+90)
- 4,518 shares@ US$2.712.7% of flowCommon StockSEC:0001104659-24-128142:1Canonical exit: 11 Mar 2025 (T+90)
- 75,000 shares@ US$2.6743.5% of flowCommon StockSEC:0001104659-24-128142:2Canonical exit: 12 Mar 2025 (T+90)
- 7,473 shares@ US$2.5911.3% of flowCommon StockSEC:0001104659-24-128142:0Canonical exit: 10 Mar 2025 (T+90)
- 320,708 shares@ US$2.3517.7% of flowCommon Stock, $0.005 Par ValueSEC:0001420506-24-002619:0
- 1,409,712 shares@ US$2.3578.3% of flowCommon Stock, $0.005 Par ValueSEC:0001420506-24-002607:0Canonical exit: 3 Mar 2025 (T+90)
- 4,000 shares0Common Stock, $.005 Par ValueSEC:0001062993-23-016986:0
- 12,700 shares@ US$4.6662.1% of flowCommon Stock, $.005 Par ValueSEC:0001062993-23-016940:0
- 14,000 shares0Common Stock, $.005 Par ValueSEC:0001062993-23-016936:0
- 14,000 shares0Common Stock, $.005 Par ValueSEC:0001062993-23-016935:0
- 14,000 shares0Common Stock, $.005 Par ValueSEC:0001062993-23-016938:0
- 14,000 shares0Common Stock, $.005 Par ValueSEC:0001062993-23-016937:0
- 375 shares@ US$4.9312.7% of flowCommon Stock, $.005 Par ValueSEC:0001062993-23-012077:0
- 1,500 shares@ US$4.9310.7% of flowCommon Stock, $.005 Par ValueSEC:0001062993-23-012074:0
- 825 shares@ US$4.934.3% of flowCommon Stock, $.005 Par ValueSEC:0001062993-23-012076:0
- 900 shares@ US$4.874.6% of flowCommon Stock, $.005 Par ValueSEC:0001062993-23-011266:0
- 1,725 shares@ US$4.8712.1% of flowCommon Stock, $.005 Par ValueSEC:0001062993-23-011264:0
- 337 shares@ US$4.8711.2% of flowCommon Stock, $.005 Par ValueSEC:0001062993-23-011265:0
- 100 shares@ US$4.953.4% of flowCommon Stock, $.005 Par ValueSEC:0001062993-22-024226:0Canonical exit: 16 Mar 2023 (T+90)
- 2,625 shares@ US$6.1824.9% of flowCommon Stock, $.005 Par ValueSEC:0001062993-22-022211:0
- 525 shares@ US$6.1823.6% of flowCommon Stock, $.005 Par ValueSEC:0001062993-22-022213:0
- 1,350 shares@ US$6.189.3% of flowCommon Stock, $.005 Par ValueSEC:0001062993-22-022214:0
- 9,000 shares0Common Stock, $.005 Par ValueSEC:0001843082-22-000034:0
25 of 401 declarations
About Psychemedics Corp
Psychemedics Corp. (ticker: PMDI) is a U.S.-based company focused on hair-based drug testing and related laboratory services. It is no longer listed on Nasdaq; following a voluntary delisting in late 2024, the common stock began trading on the OTC Market on December 13, 2024 under the PMDI symbol. The company’s corporate headquarters are now in Dallas, Texas, in the United States, after a relocation from Acton, Massachusetts. Psychemedics traces its scientific roots to the late 1970s and has marketed its hair-testing technology commercially since 1986, positioning itself as a pioneer in the category. ([psychemedics.com](https://www.psychemedics.com/about/?utm_source=openai))
From a business-model perspective, Psychemedics derives revenue primarily from drug-testing services rather than from physical consumer products. Its proprietary hair-testing platform is used by employers, government entities, law-enforcement agencies, schools, and other institutions for pre-employment screening, random testing, and policy enforcement. The company’s competitive positioning is built on scientific specialization, patent-protected methods, and a long operating history in a niche segment where client trust and analytical credibility are critical. Psychemedics consistently presents itself as the world leader in hair testing for drugs of abuse, emphasizing the method’s longer detection window versus traditional urine testing and its utility in identifying repeated or historical use patterns. ([psychemedics.com](https://www.psychemedics.com/about/?utm_source=openai))
Read moreShow less
Its offering includes hair-analysis tests covering multiple drug classes, plus a home-collection service intended for parents concerned about potential substance use by children. The company also highlights FDA 510(k)-cleared assays and a broad portfolio designed for workplace, public-sector, and family-use cases. Geographically, Psychemedics serves clients in the United States and internationally, including Fortune 500 companies and a range of public institutions. The market opportunity is niche but recurring, with demand driven by compliance, workplace safety, and the need for more persistent detection capabilities. ([psychemedics.com](https://www.psychemedics.com/about/?utm_source=openai))
Recent developments have been dominated by capital-markets restructuring and operating updates. In December 2024, the company implemented a reverse stock split followed immediately by a forward split, and it also moved from Nasdaq to OTC trading. Its third-quarter 2024 results, released in November 2024, showed lower revenue year over year for both the quarter and the first nine months, although net losses improved versus the prior-year period. For investors, the key questions are whether Psychemedics can defend its niche leadership, maintain client relationships, and convert its scientific edge into more stable financial performance after the listing change. ([investors.psychemedics.com](https://investors.psychemedics.com/news-releases/news-release-details/psychemedics-corporation-reports-third-quarter-2024-financial?utm_source=openai))
